HITGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.35 CNY | +2.85% |
|
+14.99% | -10.94% |
| Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
HitGen Inc is a China-based company mainly engaged in the early research and development of original innovative drugs. The Company focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The Company mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The Company conducts its businesses within the domestic market and to overseas markets.
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.35
CNY
Average target price
16
CNY
Spread / Average Target
+19.85%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.94% | 715M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- HitGen Receives 10 Million Yuan in Government Subsidies
